The sBLA seeks approval for Sarclisa in combination with Velcade (bortezomib), Bristol-Myers' (BMY) Revlimid (lenalidomide) and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible. With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Sep 27, 2024. A similar regulatory application is also currently under review in the European Union. The sBLA and the application in the EU were based on ...

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma Paris, May 27, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). If approved, Sarclisa ...

Sanofi (SNY) announced that it has entered into a first-in-class artificial intelligence (AI) collaboration with Formation Bio and OpenAI to build AI-powered software to expedite the development of drugs. Formation Bio is a tech-driven, AI-native pharma company focused on bringing new treatments to patients with more efficient drug development, while OpenAI is an AI research and deployment company. Per the press release, the companies are collaborating to bring together data, software and tuned models aimed ...

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the ph ...

Peter Welford - Jefferies Luisa Hector - Berenberg Graham Parry - BofA Emily Field - Barclays Emmanuel Papadakis - Deutsche bank Seamus Fernandez - Guggenheim Jo Walton - UBS David Risinger - Leerink Gary Steventon - Exane Peter Verdult - Citi We're excited about the outlook for Dupixent's potential to become a breakthrough medicine for COPD, a leading cause of death worldwide. Dupixent is well-positioned to potentially address the high unmet need in COPD with a strong clinical profile across two large Phas ...

Sanofi (NASDAQ:SNY) Barclays 26th Annual Global Healthcare Conference March 13, 2024 8:00 AM ET Company Participants Naimish Patel - Global Head of Development for Immunology and Inflammation Shaju Backer - Global Head of Immunology Franchise Conference Call Participants Emily Field - Barclays Emily Field Good morning, everybody. Thanks for joining day 2 of Barclays Global Healthcare Conference here in Miami. My name is Emily Field. I lead the European Equity Research Team, covering European Pharmaceuticals ...

Sanofi (NASDAQ:SNY) Leerink Partners Global Biopharma Conference March 12, 2024 10:40 AM ET Company Participants Naimish Patel - Global Head of Development for Immunology and Inflammation Shaju Backer - Global Head of Immunology Franchise Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. Good morning, everyone. So my name is Dave Risinger, I cover Diversified Biopharmaceuticals for Leerink Partners, and it’s very much my pleasure to welcome you to the session with Sanofi ...

Sanofi (NASDAQ:SNY) TD Cowen 44th Annual Health Care Conference March 4, 2024 12:50 PM ET Company Participants Naimish Patel - Global Head of Development for Immunology & Inflammation Erik Wallstroem - Global Head of Development for Neurology Unidentified Company Representative [Call Starts Abruptly] …with us at Cowen's 44th Annual Healthcare Conference representing the Company is Naimish Patel, who is Global Head of Development for Immunology & Inflammation; and Erik Wallstroem, who is Global Head of Devel ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

Sanofi (NASDAQ:SNY) Q4 2023 Earnings Call Transcript February 1, 2024 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head of IR Paul Hudson - CEO Houman Ashrafian - Global Head of R&D Brian Ford - EVP, Head of Specialty Care Thomas Triomphe - EVP, Vaccines Olivier Charmeil - EVP, General Medicines Julie van Ongevalle - EVP, Consumer Healthcare Jean-Baptiste de Chatillon - CFO Conference Call Participants Luisa Hector - Berenberg Jo Walton - UBS Peter Welford - Jefferies Richard Vosser - JPMorgan Grah ...